Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis

Won Jung Koh, Seung Heon Lee, Young Ae Kang, Chang Hoon Lee, Jae Chol Choi, Jae Ho Lee, Seung Hun Jang, Kwang Ha Yoo, Ki Hwan Jung, Ki Uk Kim, Sang Bong Choi, Yon Ju Ryu, Kyung Chan Kim, Soojung Um, Yong Soo Kwon, Yee Hyung Kim, Won Il Choi, Kyeongman Jeon, Yong Il Hwang, Se Joong KimYoung Seok Lee, Eun Young Heo, Juhee Lee, Yeo WoonKi, Tae Sun Shim, Jae Joon Yim

Research output: Contribution to journalArticlepeer-review

66 Citations (Scopus)


Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in theMXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in theMXF group (P = 0.75). Conclusions:ThechoiceofLFXorMXFfortreatmentofpatientswithMDRTB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with (NCT 01055145).

Original languageEnglish
Pages (from-to)858-864
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number7
Publication statusPublished - 2013 Oct 1

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Comparison of levofloxacin versusmoxifloxacin for multidrug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this